NeonMind Biosciences Inc (LCR) AI Stock Analysis

15 Followers

NeonMind Biosciences Inc

(CNQX:LCR)

Select Model

Rating:39Underperform

Price Target:CAD 0.01▼(-10.00% Downside)

Action:reiterated

Date:11/04/26

Poor financial performance from zero revenue, negative equity and cash burn is the dominant factor; weak technicals with price below moving averages and negative MACD add further downside pressure, while unfavorable valuation offers no support.

Positive Factors

Improving Cash DisciplineLower cash outflows than in prior years indicate improved spending control and may extend the company’s operating runway. However, the business remains a net cash user, so this benefit is most durable if tighter cost management continues without impairing development activity.

Negative Factors

No Revenue BaseZero reported revenue means the company has not demonstrated commercial traction or an operating base capable of funding development. Persistent losses without sales leave future progress dependent on financing and cost control, increasing uncertainty around long-term business sustainability.

NeonMind Biosciences Inc (LCR) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 1.09M
Dividend Yield: ―
Average Volume (3M): 174.09K
Price to Earnings (P/E): -0.9
Beta (1Y): 1.31
Revenue Growth: ―
EPS Growth: 57.03%
Country: Canada
Employees: 0
Sector: Basic Materials
Sector Strength: 61
Industry: Industrial Materials

NeonMind Biosciences Inc Business Overview & Revenue Model

Company Description

Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine projec...

NeonMind Biosciences Inc Financial Statement Overview

Summary

No revenue in TTM, net losses of 1.1 million, negative equity of 1.1 million, and persistent negative operating and free cash flows of 0.5 million each highlight pre-revenue stage fragility and high funding risks.

Income Statement

15Very Negative

Balance Sheet

8Very Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Jun 2024	Mar 2024	Feb 2023	Feb 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-1.02M	-1.58M	403.40K	―	-1.75M	-7.83M
Net Income	-1.28M	-1.75M	-1.54M	―	-2.03M	-7.21M
Balance Sheet
Total Assets	983.11K	1.09M	91.12K	719.33K	129.43K	1.34M
Cash, Cash Equivalents and Short-Term Investments	33.82K	206.03K	13.98K	135.40K	69.91K	967.27K
Total Debt	1.10M	1.14M	1.19M	1.04M	846.94K	450.01K
Total Liabilities	1.98M	1.74M	2.00M	1.33M	1.53M	1.05M
Stockholders Equity	-967.66K	-635.18K	-1.90M	-612.89K	-1.40M	290.30K
Cash Flow
Free Cash Flow	-794.51K	-988.65K	-89.79K	-1.31M	-1.22M	-5.82M
Operating Cash Flow	-794.52K	-988.66K	-89.79K	-1.13M	-1.08M	-5.82M
Investing Cash Flow	-258.20K	-129.42K	37.60K	-36.15K	72.14K	389.12K
Financing Cash Flow	1.06M	1.29M	0	627.93K	271.00K	6.20M

NeonMind Biosciences Inc Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.02Negative

100DMA0.02Negative

200DMA0.03Negative

Market Momentum

MACD-0.00Positive

RSI32.78Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 32.78 is Neutral, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LCR.

NeonMind Biosciences Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

TSE:LCR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
TSE:LEXT	39Underperform	CAD 1.05M	-0.59	-179.27%	―	―	71.78%
TSE:LCR	39Underperform	CAD 1.09M	-0.88	118.99%	―	―	57.03%

* Basic Materials Sector Average

Performance Comparison

TSE:LCR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:LCR	NeonMind Biosciences Inc	0.01	-0.03	-75.00%
TSE:LSD.H	Lightspeed Discoveries Inc.	0.04	0.01	40.00%
TSE:LEXT	Lexston Life Sciences Corp.	0.04	-0.27	-87.10%

NeonMind Biosciences Inc Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance

Lancaster Resources Shifts to Semi-Annual Reporting as It Launches Strategic Review

Negative

Sep 18, 2026

Lancaster Resources Inc. has adopted semi-annual financial reporting under a Canadian securities regulators’ pilot program, easing the administrative and financial burden of quarterly filings while maintaining annual and mid-year statements and conti...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026

NeonMind Biosciences Inc AI Stock Analysis